Akoya Biosciences, Inc.
AKYA
$1.14
-$0.08-6.56%
| Weiss Ratings | AKYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | AKYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | AKYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.05 | |||
| Price History | AKYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -21.38% | |||
| 30-Day Total Return | -44.39% | |||
| 60-Day Total Return | -56.49% | |||
| 90-Day Total Return | -46.23% | |||
| Year to Date Total Return | -53.09% | |||
| 1-Year Total Return | -72.99% | |||
| 2-Year Total Return | -85.61% | |||
| 3-Year Total Return | -89.42% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -73.76% | |||
| 52-Week Low % Change | 0.00% | |||
| Price | AKYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $4.65 | |||
| 52-Week Low Price | $1.22 | |||
| 52-Week Low Price (Date) | Apr 03, 2025 | |||
| 52-Week High Price (Date) | May 09, 2024 | |||
| Valuation | AKYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 60.78M | |||
| Enterprise Value | 109.88M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.12 | |||
| Earnings Per Share Growth | -24.53% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.74 | |||
| Price/Book (Q) | 7.96 | |||
| Enterprise Value/Revenue (TTM) | 1.35 | |||
| Price | $1.14 | |||
| Enterprise Value/EBITDA (TTM) | -3.28 | |||
| Enterprise Value/EBIT | -2.67 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | AKYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 49.56M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | AKYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 855 896 8401 | |||
| Address | 100 Campus Drive Marlborough, MA 01752 | |||
| Website | www.akoyabio.com | |||
| Country | United States | |||
| Year Founded | 2015 | |||
| Profitability | AKYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -50.42% | |||
| Profit Margin | -67.78% | |||
| Management Effectiveness | AKYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -16.86% | |||
| Return on Equity | -- | |||
| Income Statement | AKYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 81.67M | |||
| Total Revenue (TTM) | 81.67M | |||
| Revenue Per Share | $1.65 | |||
| Gross Profit (TTM) | 47.88M | |||
| EBITDA (TTM) | -33.53M | |||
| EBIT (TTM) | -41.18M | |||
| Net Income (TTM) | -55.37M | |||
| Net Income Avl. to Common (TTM) | -55.37M | |||
| Total Revenue Growth (Q YOY) | -19.42% | |||
| Earnings Growth (Q YOY) | 24.10% | |||
| EPS Diluted (TTM) | -1.12 | |||
| EPS Diluted Growth (Q YOY) | 24.82% | |||
| Balance Sheet | AKYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 35.04M | |||
| Cash Per Share (Q) | $0.71 | |||
| Total Current Assets (Q) | 76.73M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 7.60M | |||
| Current Ratio (Q) | 2.606 | |||
| Book Value Per Share (Q) | $0.15 | |||
| Total Assets (Q) | 125.01M | |||
| Total Current Liabilities (Q) | 29.44M | |||
| Total Debt (Q) | 84.15M | |||
| Total Liabilities (Q) | 117.41M | |||
| Total Common Equity (Q) | 7.60M | |||
| Cash Flow | AKYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -24.05M | |||
| Cash from Financing (TTM) | -3.21M | |||
| Net Change in Cash (TTM) | -71.36M | |||
| Levered Free Cash Flow (TTM) | -26.52M | |||
| Cash from Operations (TTM) | -44.10M | |||
